International Journal of Hematology

, Volume 86, Issue 5, pp 407–413 | Cite as

Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency

  • Keiko Shinozawa
  • Kagehiro Amano
  • Takashi Suzuki
  • Asashi Tanaka
  • Kenji Iijima
  • Hoyu Takahashi
  • Hiroshi Inaba
  • Katsuyuki Fukutake
Article
First Online:
Received:
Revised:
Accepted:

Abstract

We identified 3 mutations in the factor V (FV) gene(F5) associated with FV deficiency in 3 unrelated Japanese patients. Patient 1 had severe bleeding symptoms (plasma FV activity, <1%; FV antigen, 9%) and was a compound heterozygote for a novel 5-bp deletion in exon 22 and the V1813M mutation. Patient 2 had moderate bleeding symptoms (plasma FV activity, <1%; FV antigen, 4%) and was homozygous for the V1813M mutation. Patient 3 had very mild symptoms (plasma FV activity, 1%; FV antigen, 5%) and was homozygous for the novel R2174L mutation. A study of recombinant protein expression revealed that the FV coagulant-specific activities in conditioned media for the FV-R2174L and FV-V1813M mutants were reduced to approximately 40% and 28% of wild-type FV, respectively. The amounts of FV-R2174L protein and messenger RNA in the platelets of patient 3 were similar to those of healthy subjects; however, the amount of FV-V1813M protein in patient 2 was decreased. Our data suggest that the severity of the bleeding tendency in patients with FV deficiency is correlated not only with plasma FV activity but also with the amount of FV protein in the platelets.

Key words

Factor V deficiency Bleeding tendency Platelet FV 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Milstone JH. Thrombokinase as a prime activator of prothrombin: historical perspectives and present status.Fed Proc. 1964;23:742–748.PubMedGoogle Scholar
  2. 2.
    Rosing J, Tans G. Coagulation factor V: an old star shines again.Thromb Haemost. 1997;78:427–433.PubMedGoogle Scholar
  3. 3.
    Dahlbäck B. Blood coagulation.Lancet. 2000;355:1627–1632.CrossRefPubMedGoogle Scholar
  4. 4.
    Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde.Blood. 2003;101:20–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V.J Biol Chem. 1982;257:6556–6564.PubMedGoogle Scholar
  6. 6.
    Nesheim ME, Foster WB, Hewick R, Mann KG. Characterization of factor V activation intermediates.J Biol Chem. 1984;259:3187–3196.PubMedGoogle Scholar
  7. 7.
    Mann KG, Nesheim ME, Tracy PB. Molecular weight of undegraded plasma factor V.Biochemistry. 1981;20:28–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Kane WH, Majerus PW. Purification and characterization of human coagulation factor V.J Biol Chem. 1981;256:1002–1007.PubMedGoogle Scholar
  9. 9.
    Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V.Biochemistry. 1992;31:3777–3785.CrossRefPubMedGoogle Scholar
  10. 10.
    Tracy PB, Eide LL, Bowie EJ, Mann KG. Radioimmunoassay of factor V in human plasma and platelets.Blood. 1982;60:59–63.PubMedGoogle Scholar
  11. 11.
    Hayward CP, Fuller N, Zheng S, et al. Human platelets contain forms of factor V in disulfide-linkage with multimerin.Thromb Haemost. 2004;92:1349–1357.PubMedGoogle Scholar
  12. 12.
    Kane WH, Ichinose A, Hagen FS, Davie EW. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats.Biochemistry. 1987;26:6508–6514.CrossRefPubMedGoogle Scholar
  13. 13.
    Jenny RJ, Pittman DD,Toole JJ, et al. Complete cDNA and derived amino acid sequence of human Factor V.Proc Natl Acad Sci USA. 1987;84:4846–4850.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Foster WB, Nesheim ME, Mann KG. The factor Xa-catalyzed activation of factor V.J Biol Chem. 1983;258:13970–13977.Google Scholar
  15. 15.
    Wilson DB, Salem HH, Mruk JS, Maruyama I, Majerus PW. Biosynthesis of coagulation factor V by a human hepatocellular carcinoma cell line.J Clin Invest. 1984;73:654–658.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Owren PA. The coagulation of blood: investigations on a new clotting factor.Acta Med Scand. 1947;194(Suppl):1–7.Google Scholar
  17. 17.
    Peyvandi F, Mannucci PM. Rare coagulation disorders.Thromb Haemost. 1999;82:1207–1214.CrossRefGoogle Scholar
  18. 18.
    Nagaizumi K, Inaba H, Suzuki T, et al. Two double heterozygous mutations in theF7 gene show different manifestations.Br J Haematol. 2002;119:1052–1058.CrossRefGoogle Scholar
  19. 19.
    Shinozawa K. Congenital factor V deficiency and a mutation.Jpn J Thromb Hemost. 2005;16:281–296.CrossRefGoogle Scholar
  20. 20.
    Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay.Cell. 1999;96:307–310.CrossRefPubMedGoogle Scholar
  21. 21.
    Culbertson MR. RNA surveillance: unforeseen consequences for gene expression, inherited genetic disorders and cancer.Trends Genet. 1999;15:74–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Montefusco MC, Duga S, Asselta R, et al. Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations.Blood. 2003;102:3210–3216.CrossRefPubMedGoogle Scholar
  23. 23.
    Adams TE, Hockin MF, Mann KG, Everse SJ. The crystal structure of activated protein C-inactivated bovine factor Va: implications for cofactor function.Proc Natl Acad Sci USA. 2004;101:8918–8923.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cui J, O’Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal hemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V.Nature. 1996;384:66–68.CrossRefPubMedGoogle Scholar
  25. 25.
    Yang TL, Cui J, Taylor JM, Yang A, Gruber SB, Ginsburg D. Rescue of fatal neonatal hemorrhage in factor V deficient mice by low transgene expression.Thromb Haemost. 2000;83:70–77.CrossRefPubMedGoogle Scholar
  26. 26.
    Shi Q, Wilcox DA, Fahs SA, et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. JClin Invest. 2006;116:1974–1982.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Keiko Shinozawa
    • 1
  • Kagehiro Amano
    • 1
  • Takashi Suzuki
    • 1
  • Asashi Tanaka
    • 2
  • Kenji Iijima
    • 3
  • Hoyu Takahashi
    • 4
  • Hiroshi Inaba
    • 1
  • Katsuyuki Fukutake
    • 1
  1. 1.Department of Laboratory MedicineTokyo Medical UniversityShinjuku-ku, TokyoJapan
  2. 2.Department of Laboratory MedicineTokyo Medical University, Hachioji Medical CenterTokyoJapan
  3. 3.Department of Pathological Science and Technology, School of Health Science, Faculty of MedicineTottori UniversityTottoriJapan
  4. 4.Department of Internal MedicineNiigata Prefectural Kamo HospitalNiigataJapan

Personalised recommendations